Analytical Data
-
Gene name
MYCL1
- Application
-
Alternative Names
LMYC; MYCL; bHLHe38; L-Myc-1 Proto-Oncogene Protein; VMyc Class E basic helix-loop-helix protein 38
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
B4DJH2
-
Expression Region
Glu257~Tyr394
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYCL1 is a member of the MYC family of transcription factors, which play critical roles in cell proliferation, differentiation, and apoptosis. Its dysregulation is frequently implicated in various cancers, particularly in neuroblastoma and certain types of lung cancer, where MYCL1 amplification and overexpression contribute to tumorigenesis and poor prognosis. Research has shown that MYCL1 can regulate a variety of downstream target genes involved in key biological processes, such as cell cycle progression and metabolism. Understanding the functional mechanisms of MYCL1 as a transcription factor is crucial for uncovering its role in oncogenesis. To investigate these mechanisms, the creation of recombinant MYCL1 protein is essential for in vitro studies. By expressing and purifying MYCL1, researchers can explore its binding affinity to DNA, its interactions with other proteins, and its influence on gene expression. Such studies can reveal potential therapeutic targets and strategies for modulating MYCL1 activity in cancer treatment. As MYCL1 represents a promising biomarker and therapeutic target, ongoing research aims to elucidate its function in cancer biology, paving the way for novel intervention strategies against MYCL1-driven tumors.
